1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.Because yesterday, when the mood was the highest, it was inevitable that the turnover would be enlarged. Today, everyone has calmed down, and the volume will drop. Everyone's willingness to trade is not so strong. Some major institutions have done more by themselves. Typically, they don't want everyone to make money.
Judging from the rise in these directions, I think it is very simple for investors now. Just do the following:It's not to say that every time I see a good thing or a big rise, I just want to buy it, so I may be chasing high every time.Second, you must have the patience to hold shares. I told you in early trading that the market in December may be difficult as a whole, not to say that the index risk is great. Under the tone of stabilizing the stock market, there will be no big risk as a whole, but it is uncomfortable for those with high speculation.
Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.3. Generally speaking, today's shrinking and counter-pumping is basically formed, so it is ok to hold shares in the directions mentioned above.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
12-13
Strategy guide
12-13
Strategy guide
12-13